Predicate Research Report · generated 2026-08-22 · Print / save as PDF · Save to account
Hmd Biomedical, Inc. — Predicate Candidate Screening
10 FDA 510(k) clearances under this manufacturer; the 50 most recent screened below.
307 daysmedian FDA review time
511 days90th percentile
10clearances measured
| K-number | Device | Applicant | Decided | Review days | Recalls (K-match) |
|---|---|---|---|---|---|
| K212248 | GlucoLeader Enhance 2 Blood Glucose Monitoring System | Hmd Biomedical, Inc. | 2022-08-29 | 406 | 0 |
| K182428 | GlucoLeader Enhance Blood Glucose Monitoring System | Hmd Biomedical, Inc. | 2019-05-08 | 244 | 0 |
| K140150 | Goodlife AC-300 Blood Glucose Monitoring System, Goodlife AC | Hmd Biomedical, Inc. | 2015-05-14 | 477 | 0 |
| K131173 | FIA Blood Glucose Monitoring System (G2) | Hmd Biomedical, Inc. | 2014-09-18 | 511 | 0 |
| K121433 | GOODLIFE CS-200 (SINGLE PATIENT USE), CS-200 PROFESSIONAL (M | Hmd Biomedical, Inc. | 2013-02-14 | 276 | 0 |
| K113314 | PRECICHEK NS-101 POCT PROFESSIONAL BLOOD GLUCOSE MONITORING | Hmd Biomedical, Inc. | 2012-11-09 | 366 | 0 |
| K120064 | TEST, BLOOD GLUCOSE SYSTEM | Hmd Biomedical, Inc. | 2012-09-05 | 240 | 0 |
| K113307 | GL GOODLIFE SERIES BLOOD GLUCOSE MONITORING SYSMTEM | Hmd Biomedical, Inc. | 2012-07-27 | 262 | 0 |
| K032985 | GLUCOLEADER ENHANCE SELF-MONITORING OF BLOOD GLUCOSE SYSTEM | Hmd Biomedical, Inc. | 2003-10-21 | 27 | 0 |
| K023279 | GLUCOLEADER VALUE | Hmd Biomedical, Inc. | 2003-08-04 | 307 | 0 |
Methodology
Recall counts reflect FDA recall records explicitly referencing each K-number; FDA links recalls to K-numbers inconsistently, so 0 means "none found in FDA records," not "never recalled." Data: FDA openFDA, refreshed weekly. Verify decisions of consequence against the primary source. Full candidate set and CSV export: atlasbyauro.com.
Prepared with Atlas
Predicate research, review-time statistics and recall monitoring for 510(k) teams — atlasbyauro.com/fda